Mizuho raised the firm’s price target on Gilead (GILD) to $170 from $140 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong HIV Growth Priced In, Diversification Still Limited Justifying Hold Rating
- Gilead price target raised to $175 from $155 at UBS
- XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
- Gilead Sciences Earnings Call: HIV Strength, New Catalysts
- Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026